Use of akr1c3 inhibitor in preparation of drug for treating or preventing metabolic associated fatty liver disease
AssigneeShengjing Hospital of China Medical University
InventorsYang LIU, Siyu SUN
Life of this patent
Estimating the term…
Abstract
Disclosed in the present application are the use of an Aldo-Keto reductase family 1 member C3 (AKR1C3) inhibitor in the inhibition of lipid droplet generation and the promotion of lipid droplet degradation and in the preparation of a drug for treating or preventing MAFLD, a pharmaceutical composition containing the inhibitor, the use of the inhibitor as a drug for treating diseases associated with an abnormal increase in lipid droplets, a method for inhibiting Aldo-Keto reductase family 1 member C3 (AKR1C3), a method for constructing a gene engineering animal model with MAFLD, etc.
Claims24
1-3. (canceled)
Use of an aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor in the preparation of a drug for treating or preventing MAFLD.
(canceled)
(canceled)
Use of an aldo-keto reductase family 1 member C3 (AKR1C3) inhibitor in the preparation of a drug for treating or preventing a disease associated with increased lipid droplets.
16-23. (canceled)
A method for constructing a Rosa26 site-directed knock-in mouse model capable of conditionally overexpressing the AKR1C3 gene, wherein the method adopts CRISPR/Cas9 technology to insert a CAG-LSL-AKR1C3-3×flag-WPRE-pA expression cassette at the Rosa26 gene site of mouse chromosome 6 by homologous recombination to obtain the Rosa26 site-directed knock-in mouse capable of conditionally overexpressing the AKR1C3 gene.
Dependencies are inferred from the claim text.